/targeted treatments for multiple myeloma: Specific role of carfilzomib

Dhivya Sugumar, Jesse Keller, Ravi Vij

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Carfilzomib is a selective, irreversible proteasome inhibitor, initially approved in the US in 2012 as single-agent therapy for relapsed and refractory multiple myeloma. Numerous Phase II studies have evaluated carfilzomib in the relapsed and refractory as well as the newly diagnosed setting, and Phase III studies are entering their final analysis. Data continue to grow to support its use as both single-agent therapy and in combination with immunomodulatory and other novel agents. This review discusses the role of carfilzomib in the treatment of multiple myeloma. Its mechanism of action, pharmacokinetics, and role in clinical management will be reviewed.

Original languageEnglish
Pages (from-to)23-33
Number of pages11
JournalPharmacogenomics and Personalized Medicine
StatePublished - Jan 21 2015


  • Novel agents
  • Proteasome inhibitor
  • Relapsed and refractory
  • Targeted therapy


Dive into the research topics of '/targeted treatments for multiple myeloma: Specific role of carfilzomib'. Together they form a unique fingerprint.

Cite this